To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects [ Time Frame: Multiple blood and urine samples will be collected for 120 hours after dosing of DA-1229 ] [ Designated as safety issue: No ]

This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic parameters of DA-1229 as well as safety profile.